0
0
0
A bill to require a license for the reexport to an entity on the entity list of certain foreign-made items incorporating more than 10 percent of controlled United States-origin content.
2/9/2022, 1:11 AM
Congressional Summary of S 3316
This bill requires the Department of Commerce to reduce from 25% to 10% the amount of U.S.-origin components in a foreign-produced good that is exported to a company on the entity list (i.e., a company that is subject to specific license requirements for exports).
Read the Full Bill
Current Status of Bill S 3316
Bill S 3316 is currently in the status of Bill Introduced since February 13, 2020. Bill S 3316 was introduced during Congress 116 and was introduced to the Senate on February 13, 2020. Bill S 3316's most recent activity was Read twice and referred to the Committee on Banking, Housing, and Urban Affairs. as of February 13, 2020
Bipartisan Support of Bill S 3316
Total Number of Sponsors
1Democrat Sponsors
0Republican Sponsors
1Unaffiliated Sponsors
0Total Number of Cosponsors
0Democrat Cosponsors
0Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill S 3316
Primary Policy Focus
Foreign Trade and International FinancePotential Impact Areas
- Administrative law and regulatory procedures
- Computers and information technology
- Department of Commerce
- Licensing and registrations
- Trade restrictions
Alternate Title(s) of Bill S 3316
A bill to require a license for the reexport to an entity on the entity list of certain foreign-made items incorporating more than 10 percent of controlled United States-origin content.
A bill to require a license for the reexport to an entity on the entity list of certain foreign-made items incorporating more than 10 percent of controlled United States-origin content.
Comments
Sponsors and Cosponsors of S 3316
Latest Bills
Strengthening America’s Turning Point Act
Bill S 1518July 26, 2026
Unlocking Native Lands and Opportunities for Commerce and Key Economic Developments Act of 2025
Bill S 3383July 25, 2026
To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.
Bill HR 3029July 25, 2026
Transparency in Billing Act of 2026
Bill HR 8684July 25, 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Bill S 4472July 25, 2026
Connected Vehicle Security Act of 2026
Bill S 4429July 25, 2026
Protecting American Taxpayers Act
Bill S 4952July 25, 2026
National Defense Authorization Act for Fiscal Year 2027
Bill S 4784July 25, 2026
Renewing the African American Civil Rights Network Act
Bill S 4767July 25, 2026
National Plan for Epilepsy Act
Bill S 494July 25, 2026
